Vistide (Cidofovir)

Cidofovir is used for the management of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS). 

Recommended Dosage:

Induction Therapy: The recommended dose is 5 mg/kg body weight (administered as an intravenous infusion at a constant rate over 60 minutes) administered once weekly for 2-consecutive weeks. 

Maintenance Therapy: Beginning 2-weeks after the completion of induction therapy, the recommended maintenance dose is 5 mg/kg body weight (given as an intravenous infusion at a constant rate over 60 minutes) administered once every 2-weeks. 

Suspension of maintenance therapy with cidofovir should be considered as per the with local recommendations for the management of HIV infected patients.

• Cases of acute renal failure resulting in dialysis or contributing to death have occurred with as few as one or two doses of Cidofovir. Serum creatinine and urine protein must be monitored within 48 hours before each dose of Cidofovir.
• Neutropenia may occur during treatment with cidofovir 375 mg injection. Neutrophil count needs to be monitored while receiving cidofovir treatment.
• Decreased intraocular pressure may emerge while on Cidofovir therapy, and in some instances has been related to reduced visual acuity. Monitor intraocular pressure during therapy.
• Reduced serum bicarbonate related to proximal tubule injury and renal wasting syndrome (including Fanconi’s syndrome) have been seen in patients receiving cidofovir. 
• Because of the potential for the increased nephrotoxicity, doses of cidofovir greater than the recommended should not be administered and the frequency or rate of administration should not be exceeded. 
• Cidofovir injection is formulated for intravenous infusion only and should not be administered by intraocular injection. Administration of this drug by infusion should be accompanied by oral probenecid and intravenous saline prehydration. 
• Uveitis or iritis was observed in clinical trials and during postmarketing in patients with Cidofovir therapy. Treatment with topical corticosteroids with or without topical cycloplegic agents need to be considered. Monitor patients for signs/symptoms of uveitis/iritis during Cidofovir therapy.
• Patients receiving vistide injection should have regular follow-up ophthalmologic examinations. Patients may also experience certain other manifestations of CMV disease despite therapy with vistide.
• Women of childbearing age/potential should be advised that cidofovir is embryotoxic in animals and should not be used during pregnancy. Women of childbearing potential should use apt contraception during and for 30 days following treatment with Cidofovir.

What documents are required to import CIDOFOVIR to India?

CIDOFOVIR 375mg/5ml injection can be imported by patients or government hospitals on the name of the patients only.

The following documentation is required to import the product:

• Valid prescription from a qualified doctor.
• Patients’ diagnostic reports
• Patients’ ID proof (issued by the government of India)

How does the order be confirmed?

The order will be confirmed only after the receipt of:

• Valid prescription from a Doctor
• Import permit if applicable

Is CIDOFOVIR available in India?

CIDOFOVIR injection is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

Urgent Meds helps import cancer medicines on the named patient supply (NPS). Urgent Meds is a facilitator providing input on:

• Availability in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, and Pune, etc.)
• Medicine Price.
• Finding genuine and reliable sources from Canada, Europe, USA, and Australia
• Ensuring 100% transparency.

CIDOFOVIR can be made available to patients, doctors, and hospitals in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, Pune, and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and import permit.

Urgent Meds can facilitate the supply of CIDOFOVIR (prescription medicines) to all locations in the world and in India after fulfilling the legal requirements (if applicable).

Please contact +1-647-818-4196 or write to us at info@urgentmeds.in for CIDOFOVIR injection price in India.

We guarantee quality and delivery anywhere in the world as per the buyer’s requirement

Urgent Meds is able to source CIDOFOVIR (Cancer Treatment Medicines) from across the globe and has the ability to supply. Urgent Meds offers its customers worldwide access to the best available treatment.

Urgent Meds is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the patient’s address only from New Delhi, India.

What is the Generic Name for the trade name drug Vistide®?

Cidofovir is the Generic Name for the trade name drug Vistide®.

What is the Manufacturer Name of Vistide®?

Vistide® is manufactured by Gilead Sciences.

Is Vistide® approved by the FDA?

Yes, Vistide® is approved by the FDA. Date of approval: June 1996.

What is the dosage and form of Cidofovir supplied?

Cidofovir is supplied as Injection: 375mg/5ml for intravenous administration.

What are the most common side effects due to Vistide®?

Most common side effects due to Vistide® include chills, dose-dependent nephrotoxicity, neutropenia, metabolic acidosis, anterior uveitis, proteinuria, nausea, vomiting, asthenia, rash, headache, diarrhea, alopecia, infection, anorexia, dyspnea, anemia, and abdominal pain.

How much does Cidofovir cost in India?

The cidofovir cost in India is reasonable and can vary. In order to procure this CMV retinitis drug authentically, you can call or WhatsApp +1-647-818-4196 or send mail to info@urgentmeds.in.

What are the storage conditions of Vistide®?

Vistide (Cidofovir) should be stored at controlled room temperature 20 °C to 25 °C (68 °F to 77 °F).